KalVista Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is May - April.

Millions USD. Fiscal year is May - Apr.

Year	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013 - 2012
Net Income	-92.91	-82.34	-46.24	-29.12	-20.82	-15.81	-18.6	-11.44	-7.23	-13.36	Upgrade
Depreciation & Amortization	0.8	0.74	0.65	0.53	0.38	0.18	0.04	0.03	0.04	0.05	Upgrade
Share-Based Compensation	9.92	11.09	7.12	4.45	2.97	1.06	0.39	0.12	0.04	0.38	Upgrade
Other Operating Activities	6.92	-7.62	8.3	-20.67	-18.89	25.12	-5.55	-1.87	0.78	1.67	Upgrade
Operating Cash Flow	-75.26	-78.13	-30.17	-44.82	-36.37	10.56	-23.72	-13.16	-6.37	-11.25	Upgrade
Capital Expenditures	-1.2	-0.93	-0.08	-0.22	-1.08	-1.43	-0.07	-0.01	-0.13	-0.16	Upgrade
Acquisitions	0	0	0	0	0	0	34.14	0	0	0	Upgrade
Change in Investments	42.61	58.79	-147.57	16.97	-68.34	0	0	0	0	0	Upgrade
Investing Cash Flow	41.42	57.86	-147.65	16.75	-69.42	-1.43	34.07	-0.01	-0.13	-0.16	Upgrade
Share Issuance / Repurchase	57.03	1.58	212.12	11.64	88.15	9.14	0	0	0	-0.97	Upgrade
Debt Issued / Paid	0	0	0	-0.05	-0.21	-0.15	0	0	0	6.5	Upgrade
Other Financing Activities	1.09	-	-	-	-	-	-	33	8.66	-	Upgrade
Financing Cash Flow	58.12	1.58	212.12	11.58	87.94	8.99	0	33	8.66	5.53	Upgrade
Exchange Rate Effect	1.24	-1.17	0.51	0.26	-1.21	1.99	-1.16	-0.6	-0.12	0	Upgrade
Net Cash Flow	25.51	-19.86	34.8	-16.22	-19.05	20.11	9.19	19.24	2.05	-5.88	Upgrade
Free Cash Flow	-76.46	-79.07	-30.25	-45.04	-37.45	9.13	-23.8	-13.17	-6.49	-11.41	Upgrade
Free Cash Flow Margin	-	-	-	-354.89%	-232.19%	108.78%	-1582.18%	-617.30%	-	-39351.72%	Upgrade
Free Cash Flow Per Share	-2.74	-3.23	-1.58	-2.54	-2.48	0.89	-5.12	-22.27	-24.66	-260.83	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).